Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Ensuring the Health of GPO Relationships

Maintaining financial stability is critical for healthcare organizations. The key to protecting bottom lines is ensuring the relationships with the hospital’s group purchasing organizations (GPOs) are both healthy and beneficial. While the purpose of the GPO is securing the best possible product value for hospital members, there is often room for improvement. With an average…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Maintaining financial stability is critical for healthcare organizations. The key to protecting bottom lines is ensuring the relationships with the hospital’s group purchasing organizations (GPOs) are both healthy and beneficial. While the purpose of the GPO is securing the best possible product value for hospital members, there is often room for improvement. With an average of 72% of hospital purchases being made via GPO contracts, there is a tremendous opportunity for significant cost savings by taking a closer look at these relationships.

Supplementing GPO Value for the Healthiest Supplier Relationships

GPOs negotiate with suppliers on behalf of multiple healthcare organizations to secure high-value agreements. However, several factors can hinder their efforts. Shifts in the market can skew the savings that are achievable on different product lines. If the GPO does not regularly review and renegotiated its portfolio of contracts, the current savings opportunities may no longer be competitive. When GPOs fail to react to a fluctuating market, hospitals may miss out on opportunities to reduce costs.

As an alternative, in some cases, utilizing direct contracts or partnering with regional coalitions allow hospitals more flexibility in responding to certain shifts and can yield cost reductions greater than what the established GPO supply contracts can offer. In short, GPO relationships must be analyzed and monitored regularly to ensure hospitals are receiving the best value possible at any given time.

TPC Protects the Health of Bottom Lines

As mentioned, hospitals generally purchase the majority of their products and services via GPOs. While they achieve enhanced value on many items—especially commodities—they may not achieve the best possible value on all items. That’s when hospitals generally employ alternative contracting strategies to negotiate better opportunities, usually on more specific items like physician preference (PPI). To that end, hospitals that engage with TPC have a partner to help them aggregate volume with other Members for regional purchasing power to drive incremental value which allows them to better optimize their GPO relationship.

In other words, TPC is a healthcare facility’s GPO advocate–fostering a mutually beneficial partnership between all parties that results in reducing a hospital’s expenditures. Our supply chain optimization services are focused on delivering direct business value.

Time for a GPO Check Up

Analyzing expenditures on a categorical basis can identify opportunities to reduce spending. When it comes to optimizing the GPO relationship, TPC has the expertise and experience. TPC works tirelessly to ensure Member hospitals are receiving the maximum value for each dollar spent by implementing collaborative strategies to improve financial, operational and clinical performance.

Boosting GPO Effectiveness with TPC

Purchasing in the healthcare industry can be a complex and arduous task, making it difficult to determine whether an organization is receiving best in class value. TPC provides the framework to guarantee facilities are generating the greatest value possible from their supplier relationships, ensuring hospitals can continue to deliver the uninterrupted, high quality care their patients deserve.

Contact our team of experts to learn more about how TPC can optimize the health of your GPO relationship!

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512